Last reviewed · How we verify
Triple antithrombotic therapy
Triple antithrombotic therapy combines three anticoagulant or antiplatelet agents to prevent blood clot formation through multiple complementary pathways.
Triple antithrombotic therapy combines three anticoagulant or antiplatelet agents to prevent blood clot formation through multiple complementary pathways. Used for Acute coronary syndrome with concurrent indication for anticoagulation, Atrial fibrillation with acute coronary syndrome or recent percutaneous coronary intervention.
At a glance
| Generic name | Triple antithrombotic therapy |
|---|---|
| Also known as | TAT |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | Antithrombotic combination therapy |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This regimen typically combines an anticoagulant (such as warfarin or a direct oral anticoagulant) with dual antiplatelet therapy (aspirin and a P2Y12 inhibitor like clopidogrel). The combination targets different steps in the coagulation cascade and platelet aggregation, providing enhanced thrombotic protection in high-risk cardiovascular conditions. However, this approach significantly increases bleeding risk and is used selectively in specific clinical scenarios.
Approved indications
- Acute coronary syndrome with concurrent indication for anticoagulation
- Atrial fibrillation with acute coronary syndrome or recent percutaneous coronary intervention
Common side effects
- Major bleeding
- Minor bleeding
- Gastrointestinal hemorrhage
- Intracranial hemorrhage
Key clinical trials
- REGistry of Long-term AnTithrombotic TherApy-2
- REGistry of Long-term AnTithrombotic TherApy-1
- LAAO Versus NOAC in Patients with AF and PCI (NA)
- NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI (PHASE4)
- What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? (PHASE4)
- STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial (NA)
- Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4) (PHASE4)
- Safety of "Ticagrelor+ Warfarin"in Comparison With "Clopidogrel+Aspirin+Warfarin" (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: